Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase I, Open-label Study to Evaluate the Ability of UB-612 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines

NCT05167253 is registered in ClinicalTrials.gov with United Biomedical Inc., Asia as lead sponsor.

NCT NCT05167253
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05167253 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase I, Open-label Study to Evaluate the Ability of UB-612 Vaccine to Boost Immunity of Heterologous COVID-19 Vaccines
Lead sponsor
United Biomedical Inc., Asia
Phase
Phase 1
Overall status
Withdrawn
Start date
February 15, 2022
Completion date
October 31, 2022
Enrollment
0 (actual)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

covid-19